SPIRIT IV trial design: A large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease

American Heart Journal

Volumn 158, Issue 4, 2009, Pages

  Nikolsky, Eugenia ^a   Lansky, Alexandra J ^a   Sudhir, Krishnankutty ^d   Doostzadeh, Julie ^b   Cutlip, Donald E ^b   Piana, Robert ^c   Su, Xiaolu ^d   White, Roseann ^d   Simonton, Charles A ^d   Stone, Gregg W ^a  

^a NewYork Presbyterian Hospital   (United States)

^b HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d ABBOTT VASCULAR   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; PACLITAXEL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; METHODOLOGY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; SINGLE BLIND PROCEDURE; UNITED STATES;

EID: 70349205363     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.07.025     Document Type: Article

References (41)

1. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
2. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
3. Stone G.W., Ellis S.G., Cannon L., et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 294 (2005) 1215-1223
4. Fajadet J., Wijns W., Laarman G.J., et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 114 (2006) 798-806
5. Finn A.V., Joner M., Nakazawa G., et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115 (2007) 2435-2441
6. Camenzind E., Steg P.G., and Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 115 (2007) 1440-1455
7. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
8. Lagerqvist B., James S.K., Stenestrand U., et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
9. Windecker S., Remondino A., Eberli F.R., et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 353 (2005) 653-662
10. Goy J.J., Stauffer J.C., Siegenthaler M., et al. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol 45 (2005) 308-311
11. Morice M.C., Colombo A., Meier B., et al. Sirolimus-vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 295 (2006) 895-904
12. Mehilli J., Dibra A., Kastrati A., et al. Randomized trial of paclitaxel-and sirolimus-eluting stents in small coronary vessels. Eur Heart J 27 (2006) 260-266
13. Galløe A.M., Thuesen L., Kelbaek H., et al. Comparison of paclitaxel-and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA 299 (2008) 409-416
14. Schömig A., Dibra A., Windecker S., et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 50 (2007) 1373-1380
15. Lassen J.F., Rasmussen K., Galløe A., et al. SORT-OUT III: A Prospective, Randomized Comparison of Zotarolimus-eluting and Sirolimus-eluting Stents in Patients with Coronary Artery Disease. Paper presented at: Transcatheter Therapeutics October 16, Washington, DC (2008)
16. Sheiban I., Villata G., Bollati M., et al. Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V). Vasc Health Risk Manag 4 (2008) 31-38
17. Schuler W., Sedrani R., Cottens S., et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64 (1997) 36-42
18. Carter A.J., Brodeur A., Collingwood R., et al. Experimental efficacy of an everolimus eluting cobalt chromium stent. Catheter Cardiovasc Interv 68 (2006) 97-103
19. Joner M., Nakazawa G., Finn A.V., et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 52 (2008) 333-442
20. Serruys P.W., Ong A.T.L., Piej J.J., et al. A randomised comparison of a durable polymer everolimus-eluting coronary stent with a bare metal coronary stent. EuroIntervention 1 (2005) 58-65
21. Serruys P.W., Ruygrok P., Neuzner J., et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention 2 (2006) 286-294
22. Stone G.W., Midei M., Newman W., et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299 (2008) 1903-1913
23. Miu R., Serruys P.W., and Stone G.W. Performance of everolimus-eluting stents: pooled analysis from the SPIRIT trials. J of Intervent Cardiol (2009) [In press]
24. Stone G.W., Midei M., Newman W., et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation 119 (2009) 680-686
25. ten Berg J., Kelder J., Suttorp M., et al. Influence of planned six-month follow-up angiography on large outcome after percutaneous coronary intervention: a randomized study. J Am Coll Cardiol 38 (2001) 1061-1069
26. Pinto D.S., Stone G.W., Ellis S.G., et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol 48 (2006) 32-36
27. Stone G.W., Lansky A.J., Pocock S.J., et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 360 (2009) 1946-1959
28. Iijima R., Ndrepepa G., Mehilli J., et al. Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. Am Heart J 154 (2007) 688-693
29. Popma J.J., Leon M.B., Moses J.W., et al. Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation 110 (2004) 3773-3780
30. Sabate M., Jimenez-Quevedo P., Angiolillo D.J., et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. Circulation 112 (2005) 2175-2183
31. Moussa I., Leon M.B., Baim D.S., et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109 (2004) 2273-2278
32. Hermiller J.B., Raizner A., Cannon L., et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 45 (2005) 1172-1179
33. Kimura M., Mintz G.S., Weissman N.J., et al. Meta-analysis of the effects of paclitaxel-eluting stents versus bare metal stents on volumetric intravascular ultrasound in patients with versus without diabetes mellitus. Am J Cardiol 101 (2008) 1263-1268
34. Dibra A., Kastrati A., Mehilli J., et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353 (2005) 663-670
35. Ong A.T., Aoki J., van Mieghem C.A., et al. Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus-versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). Am J Cardiol 96 (2005) 358-362
36. Maeng M., Jensen L.O., Galloe A.M., et al. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial. Am J Cardiol 103 (2009) 345-349
37. Kim J.S., Lee B.H., Ko Y.G., et al. Comparison of sirolimus-eluting stent and paclitaxel-eluting stent for long-term cardiac adverse events in diabetic patients: the Korean Multicenter Angioplasty Team (KOMATE) Registry. Catheter Cardiovasc Interv 72 (2008) 601-607
38. Mahmud E., Bromberg-Marin G., Palakodeti V., et al. Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. J Am Coll Cardiol 51 (2008) 2385-2395
39. Mitsuuchi Y., Johnson S.W., Selvakumaran M., et al. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res 60 (2000) 5390-5394
40. King III S.B., Smith Jr. S.C., Hirshfeld Jr. J.W., et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 51 (2008) 172-209
41. Cutlip D.E., Windecker S., Mehran R., et al., on behalf of the Academic Research Consortium. Academic Research Consortium, clinical endpoints in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351